These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36880014)

  • 1. A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects.
    Cheng Y; Ye Y; Gaudy A; Ghosh A; Xue Y; Wang A; Zhou S; Li Y
    Clin Pharmacol; 2023; 15():9-19. PubMed ID: 36880014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma.
    Cheng Y; Xue Y; Chen L; Masin M; Maciag P; Peluso T; Zhou S; Li Y
    Br J Clin Pharmacol; 2023 Jan; 89(1):316-329. PubMed ID: 35981078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I, Open-Label, Mass Balance Study of [
    Cheng Y; Wang X; Liu L; Silva J; Thomas M; Li Y
    Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):355-365. PubMed ID: 38521893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.
    Gaudy A; Atsriku C; Ye Y; MacGorman K; Liu L; Xue Y; Surapaneni S; Palmisano M
    Eur J Clin Pharmacol; 2021 Feb; 77(2):223-231. PubMed ID: 32965548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
    Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
    Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
    Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
    Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study
.
    Shakeri-Nejad K; Aslanis V; Veldandi UK; Gardin A; Zaehringer A; Dodman A; Su Z; Legangneux E
    Int J Clin Pharmacol Ther; 2017 Jan; 55(1):41-53. PubMed ID: 27443658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Mild and Moderate Hepatic Impairment (Defined by Child-Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics.
    Zahir H; Greenberg J; Hsu C; Marbury TC; Lasseter KC; Xu LA; Tap WD; Healey JH; Stacchiotti S; LaCreta F
    J Clin Pharmacol; 2022 Aug; 62(8):992-1005. PubMed ID: 35247274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant.
    Dayal S; Aluri J; Hall N; Filippov G; Moline M; Reyderman L; Landry I
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00758. PubMed ID: 33822479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
    Horsmans Y; Zhou J; Liudmila M; Golor G; Shibolet O; Quinlan M; Emotte C; Boss H; Castro H; Sellami D; Preston RA
    Clin Pharmacokinet; 2018 Mar; 57(3):345-354. PubMed ID: 28577129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
    Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
    Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
    Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
    Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
    Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
    Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
    Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
    Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
    Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
    Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment.
    Xu Y; Izumi R; Nguyen H; Kwan A; Kuo H; Madere J; Slatter JG; Podoll T; Vishwanathan K; Marbury T; Smith W; Preston RA; Sharma S; Ware JA
    J Clin Pharmacol; 2022 Jun; 62(6):812-822. PubMed ID: 34897701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.
    Kasichayanula S; Liu X; Zhang W; Pfister M; LaCreta FP; Boulton DW
    Clin Ther; 2011 Nov; 33(11):1798-808. PubMed ID: 22030444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment.
    Wang J; Wang X; Zhang ZY; Arora S; Lu S; Kansra V
    J Clin Pharmacol; 2018 May; 58(5):686-693. PubMed ID: 29329482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment.
    Boinpally R; Alcorn H; Adams MH; Longstreth J; Edwards J
    Clin Drug Investig; 2013 Mar; 33(3):199-206. PubMed ID: 23417352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
    Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.